Novo HRS-1596 is the subject of a new exclusive license agreement announced on 29 September 2026 from Bagsværd, Denmark, under which Novo gains rights to a phase 1-ready oral candidate from Hengrui Pharma (600276.SH; 01276.HK). HRS-1596 is a glucagon-like peptide-1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist with potential for once-weekly oral dosing. The announcement adds a new dual-receptor asset to Novo’s pipeline across obesity, diabetes and other cardiometabolic diseases.
The financial headline is substantial. According to the official Novo Nordisk announcement, the total potential value of the agreement is up to 2.6 billion US dollars, contingent on applicable development, regulatory and commercial milestones. That figure includes a 300 million dollar upfront payment. Hengrui Pharma is also eligible to receive royalties based on net sales within the licensed territory.
Because the compound is described as phase 1-ready, most of the potential value depends on future milestones rather than the upfront cash. By our own calculation, the 300 million dollar upfront payment equals roughly 11.5 percent of the 2.6 billion dollar maximum. Novo’s executives framed the deal as part of a wider strategy in GLP-1/GIP dual agonist research and oral peptide development, which the company says it has pioneered.
Novo HRS-1596 Agreement: Exclusive Rights, Territory and Financial Terms
Under the terms of the agreement, Novo obtains exclusive rights to develop, manufacture and commercialize HRS-1596 globally. Four markets are excluded from the license: mainland China, Hong Kong, Macao and Taiwan. The exclusive rights therefore span the full development, manufacturing and commercial chain in every other market.
The financial structure of the Novo Nordisk HRS-1596 deal has three disclosed components: a 300 million dollar upfront payment, milestone payments tied to development, regulatory and commercial achievements, and royalties on net sales in the licensed territory. The announcement does not disclose the size of individual milestones, the royalty rate or the number of milestone tiers. Those items are labeled “Not disclosed” in this article, and we have not estimated them.
Hengrui Pharma’s leadership also commented on the agreement. Frank Jiang, MD, Ph.D., Executive Vice President and Chief Strategy Officer of Hengrui Pharma, said the collaboration brings together Hengrui’s innovation strengths and Novo’s global leadership in GLP-1 therapies and obesity care. He described HRS-1596 as reflecting a commitment to metabolic disease innovation. Hengrui Pharma says it has focused on oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience since its founding in 1970.
How Novo Nordisk HRS-1596 Works: GLP-1 and GIP Dual Receptor Agonism
According to the announcement, HRS-1596 is designed to reduce weight and improve glycemic control through multiple mechanisms. These include appetite suppression, stimulation of insulin secretion and improved insulin sensitivity. The Novo Nordisk HRS-1596 mechanism combines activity at both GLP-1R and GIPR, which is why the molecule is classed as a dual receptor agonist rather than a single-target GLP-1 drug.
The main commercial promise is convenience. The announcement states that HRS-1596 has potential to be developed for once-weekly oral administration, which would substantially reduce dosing frequency and improve convenience compared with current offerings. Martin Holst Lange, executive vice president, Research & Development and chief scientific officer at Novo, said the company is excited to explore whether the molecule can “raise the bar for convenience.” This is forward-looking language, and once-weekly oral dosing has not been demonstrated in clinical data released so far.
The potential uses named in the announcement are obesity, type 2 diabetes and other metabolic diseases. HRS-1596 has not been approved anywhere, and the announcement does not include efficacy or safety data. Any future marketing authorisation would require review by regulators such as the U.S. Food and Drug Administration.
Novo HRS-1596 Development Status and Novo’s Oral Pipeline Strategy
Development is at an early stage. Hengrui Pharma has received approval in China to initiate phase 1 clinical trials with HRS-1596 for weight management and type 2 diabetes. For Novo Nordisk HRS-1596 the practical implication is that human data is still ahead. The announcement does not give a trial registration number, start date, dose range or enrollment size, and those items are Not disclosed.
Lange said Novo has pioneered the field of oral peptides and continues to advance its “broad and deep oral pipeline” across obesity, diabetes and other cardiometabolic diseases. He attributed that progress to strong internal capabilities and leading external innovation. This license is an example of the external route. Novo describes itself as a global healthcare company with over 67,000 employees and more than a century of scientific experience.
Several important questions remain unanswered in the source material. It does not say when Novo expects to begin its own trials, whether Novo will run global phase 1 studies, or what manufacturing plans exist. It also gives no clinical results, pharmacokinetic data or comparison with existing treatments.
Novo HRS-1596 Closing Conditions, Timeline and What to Watch
The license agreement is subject to clearance under the U.S. Hart-Scott-Rodino Antitrust Improvements Act and the satisfaction of other customary closing conditions. The transaction is expected to close in the fourth quarter of 2026. The Hart-Scott-Rodino process is administered by the Federal Trade Commission’s Premerger Notification Program. The closing timeline is a forward-looking expectation, and the announcement does not guarantee it.
Three developments will matter next: confirmation that the antitrust and closing conditions are met, any disclosure of the first phase 1 trial details, and updates to Novo’s oral pipeline in its regular communications.
